POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. BSEM, a number one MedTech firm centered on the event, manufacturing, and commercialization of placental-derived merchandise for superior wound care, declares the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane – Diabetic Foot Ulcers) medical trial to guage Vendaje® versus customary of look after sufferers struggling with non-healing diabetic foot ulcers.
Jason Matuszewski, CEO of BioStem Applied sciences, commented: “We’re dedicated to advancing medical trials that benchmark our merchandise in opposition to the usual of care. Whereas Vendaje is already commercially accessible, demonstrating medical effectiveness is essential to driving elevated market adoption. Vendaje is an revolutionary wound care choice for sufferers with continual, non-healing wounds, and this trial represents a key milestone in showcasing our BioREtain expertise inside the diabetic foot ulcer market. As we proceed to onboard sufferers for the trial, we look ahead to sharing updates on key medical milestones.”
BR-AM-DFU Scientific Trial Overview and Design:
- Title: Non-healing Diabetic Foot Ulcers Handled with Commonplace Care, With or With out BR-AM
- Major Final result Measures: The first goal of this research is to evaluate whether or not the addition of Vendaje to plain care will increase the chance of attaining full wound closure in diabetic foot ulcers (DFUs) in comparison with customary care alone. The research will consider the proportion of topics who obtain full wound closure, outlined as 100% reepithelialization, over a 12-week therapy interval.
- ClinicalTrials.gov Hyperlink: HERE
The BR-AM-DFU trial is a multicenter, randomized, managed research that can enroll 60 sufferers with non-healing DFUs at roughly twelve websites throughout america. The research will deal with a affected person inhabitants with diabetic foot ulcers (DFUs) which have sufficient perfusion and no medical indicators or signs of an infection. Weekly visits will probably be carried out to observe compliance with wound care protocols and off-loading, in addition to to doc when wound closure is achieved. A follow-up section will start for all topics that obtain full wound closure, which is designed to measure longevity and sturdiness of the closed wound. This follow-up will encompass a four-week interval with two visits at every two-week interval.
Supporting Ongoing Scientific Trials:
That is the second medical trial launched by BioStem that’s actively enrolling sufferers. The primary trial, BR-AC-DFU-101 (BioREtain® – Amnion Chorion – Diabetic Foot Ulcers), was initiated in October 2024 and is evaluating the effectiveness of the corporate’s AmnioWrap2™ placental tissue in treating sufferers with DFUs. To study extra about that trial, please go to the trial overview on ClinicalTrials.gov.
Diabetic Foot Ulcers Market Statistics:
Diabetic foot ulcers (DFUs) are a severe and continual situation affecting tens of millions of people inside the diabetic inhabitants. In keeping with the American Podiatric Medical Affiliation (APMA), a number one authority on foot and ankle well being, roughly 15% of individuals with diabetes will develop foot ulcers. Alarmingly, 6% of those people might require hospitalization because of infections or different problems associated to their ulcers. The dangers for diabetic sufferers are substantial, as DFUs are the main reason for decrease extremity amputations within the U.S. Research point out that between 14% and 24% of people with diabetes who develop foot ulcers will in the end want an amputation.
Latest information evaluation from GlobalData Plc., a distinguished international information supplier, revealed that 2.2 million sufferers obtained therapy for DFUs in 2023, with numbers projected to rise within the coming years. The financial burden of those ulcers on healthcare techniques is critical, with annual therapy prices estimated between $9 billion and $13 billion in america alone.
About BioREtain®:
BioStem’s placental allografts are processed using the Firm’s proprietary BioREtain® technique, which preserves the tissue’s endogenous organic properties whereas sustaining the construction and matrix present in contemporary perinatal tissue. The patented six-step BioREtain® course of is mild, minimally invasive, and preserves the pure integrity of the amniotic tissue/elements important to the wound therapy course of. For a full overview of BioREtain, please go to: https://biostemtechnologies.com/our-science/#six-steps.
Be part of BioStem’s Distribution Listing & Social Media:
To observe the newest developments at BioStem, sign-up to the Firm’s e-mail distribution record HERE, and observe us on Twitter and LinkedIn.
About BioStem Applied sciences, Inc. BSEM:
BioStem Applied sciences is a number one innovator centered on harnessing the pure properties of perinatal tissue within the growth, manufacture, and commercialization of allografts. The Firm is targeted on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing technique. BioREtain® has been developed by making use of the newest analysis in superior wound care, centered on sustaining development elements and preserving tissue construction. BioStem Applied sciences’ high quality administration system and customary working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These techniques and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers consists of AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem Applied sciences placental allograft is processed on the Firm’s FDA registered and AATB accredited web site in Pompano Seaside, Florida. For extra data go to biostemtechnologies.com and observe us on Twitter and LinkedIn.
Ahead-Trying Statements:
Apart from statements of historic truth, this launch additionally incorporates forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases equivalent to “forecast,” “intend,” “search,” “goal,” “anticipate,” “consider,” “anticipate,” “estimate,” “plan,” “outlook,” and “mission” and different related expressions that predict or point out future occasions or tendencies or that aren’t statements of historic issues. Ahead-looking statements with respect to the operations of the Firm, methods, prospects and different features of the enterprise of the Firm are based mostly on present expectations which are topic to identified and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. These elements embrace, however should not restricted to: (1) the influence of any modifications to the reimbursement ranges for the Firm’s merchandise; (2) the Firm faces important and persevering with competitors, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; (3) speedy technological change might trigger the Firm’s merchandise to change into out of date and if the Firm doesn’t improve its product choices by way of its analysis and growth efforts, it could be unable to successfully compete; (4) to be commercially profitable, the Firm should persuade physicians that its merchandise are protected and efficient options to current therapies and that its merchandise needs to be used of their procedures; (5) the Firm’s potential to boost funds to broaden its enterprise; (6) the Firm has incurred important losses since inception and should incur losses sooner or later; (7) modifications in relevant legal guidelines or rules; (8) the chance that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive elements; (9) the Firm’s potential to take care of manufacturing of its merchandise in ample portions to satisfy demand; and (10) the COVID-19 pandemic and its influence, if any, on the Firm’s fiscal situation and outcomes of operations; You might be cautioned to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. Though it could voluntarily accomplish that infrequently, the Firm undertakes no dedication to replace or revise the forward-looking statements, whether or not on account of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.
Telephone: 954-380-8342
Web site: http://www.biostemtechnologies.com
E-Mail: [email protected]
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
PCG Advisory
Jeff Ramson
[email protected]
646-863-6893
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
